Oppenheimer Asset Management Inc. Increases Stock Position in Glaukos Corporation $GKOS

Oppenheimer Asset Management Inc. grew its position in shares of Glaukos Corporation (NYSE:GKOS) by 55.9% during the 3rd quarter, according to the company in its most recent disclosure with the SEC. The fund owned 22,289 shares of the medical instruments supplier’s stock after purchasing an additional 7,992 shares during the quarter. Oppenheimer Asset Management Inc.’s holdings in Glaukos were worth $1,818,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors have also made changes to their positions in the company. State Street Corp lifted its holdings in shares of Glaukos by 5.3% during the second quarter. State Street Corp now owns 2,090,365 shares of the medical instruments supplier’s stock worth $215,914,000 after purchasing an additional 105,972 shares during the period. Ameriprise Financial Inc. lifted its stake in shares of Glaukos by 3.5% in the 2nd quarter. Ameriprise Financial Inc. now owns 1,999,252 shares of the medical instruments supplier’s stock worth $206,503,000 after acquiring an additional 68,497 shares during the period. Primecap Management Co. CA boosted its holdings in shares of Glaukos by 50.0% in the second quarter. Primecap Management Co. CA now owns 1,827,998 shares of the medical instruments supplier’s stock valued at $188,814,000 after acquiring an additional 609,523 shares in the last quarter. Geode Capital Management LLC boosted its holdings in shares of Glaukos by 9.5% in the second quarter. Geode Capital Management LLC now owns 1,330,593 shares of the medical instruments supplier’s stock valued at $137,454,000 after acquiring an additional 115,529 shares in the last quarter. Finally, Westfield Capital Management Co. LP increased its stake in shares of Glaukos by 7.7% during the second quarter. Westfield Capital Management Co. LP now owns 1,167,853 shares of the medical instruments supplier’s stock worth $120,628,000 after acquiring an additional 83,669 shares during the period. Institutional investors and hedge funds own 99.04% of the company’s stock.

Glaukos Trading Up 2.6%

NYSE:GKOS opened at $109.51 on Friday. Glaukos Corporation has a 52-week low of $73.16 and a 52-week high of $161.78. The company has a quick ratio of 4.47, a current ratio of 5.20 and a debt-to-equity ratio of 0.09. The stock has a fifty day simple moving average of $114.64 and a 200-day simple moving average of $97.97. The company has a market capitalization of $6.29 billion, a PE ratio of -71.11 and a beta of 0.70.

Analyst Ratings Changes

A number of brokerages recently commented on GKOS. William Blair upgraded shares of Glaukos to a “strong-buy” rating in a research report on Friday, January 30th. Wall Street Zen raised Glaukos from a “hold” rating to a “buy” rating in a report on Saturday, February 7th. Piper Sandler restated an “overweight” rating and issued a $165.00 price target on shares of Glaukos in a research note on Wednesday, January 14th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Glaukos in a report on Thursday, January 22nd. Finally, Stephens increased their price objective on Glaukos from $115.00 to $145.00 and gave the stock an “overweight” rating in a research report on Friday, January 2nd. One equities research analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating, one has issued a Hold rating and two have issued a Sell rating to the company. Based on data from MarketBeat, Glaukos has a consensus rating of “Moderate Buy” and an average target price of $132.54.

Insider Activity at Glaukos

In other Glaukos news, COO Joseph E. Gilliam sold 19,340 shares of the company’s stock in a transaction dated Tuesday, November 18th. The shares were sold at an average price of $90.00, for a total value of $1,740,600.00. Following the sale, the chief operating officer owned 92,366 shares of the company’s stock, valued at $8,312,940. This represents a 17.31% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Alex R. Thurman sold 315 shares of the stock in a transaction that occurred on Tuesday, November 25th. The shares were sold at an average price of $105.00, for a total transaction of $33,075.00. Following the completion of the sale, the chief financial officer owned 50,488 shares in the company, valued at $5,301,240. This represents a 0.62% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 329,655 shares of company stock valued at $37,752,234 in the last quarter. 5.80% of the stock is owned by corporate insiders.

About Glaukos

Glaukos Corporation is a medical technology company specializing in the development, manufacturing and commercialization of innovative therapies for patients with glaucoma and other chronic eye diseases. The company’s core offerings focus on micro-invasive glaucoma surgery (MIGS), designed to reduce intraocular pressure and manage glaucoma more safely and effectively than traditional surgical approaches. Glaukos’s flagship products include the iStent, iStent inject and iStent infinite trabecular micro-bypass stents, which are implanted during cataract surgery to improve aqueous outflow and help control eye pressure.

Beyond its MIGS portfolio, Glaukos has expanded into sustained drug-delivery solutions.